
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3031355/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	9.4	28
2	The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition. PLoS Genetics, 2020, 16, e1009164.	3.5	8
3	Title is missing!. , 2020, 16, e1009164.		Ο
4	Title is missing!. , 2020, 16, e1009164.		0
5	Title is missing!. , 2020, 16, e1009164.		0
6	Title is missing!. , 2020, 16, e1009164.		0
7	Title is missing!. , 2020, 16, e1009164.		0
8	Title is missing!. , 2020, 16, e1009164.		0
9	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine, 2019, 46, 94-104.	6.1	24
10	Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. Nature Communications, 2019, 10, 4622.	12.8	64
11	Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Cancers, 2019, 11, 126.	3.7	29
12	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	3.4	153
13	Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 2019, 11, 795.	3.7	17
14	Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach. Molecular and Cellular Oncology, 2019, 6, 1610322.	0.7	8
15	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proceedings of the United States of America, 2019, 116, 9020-9029.	7.1	372
16	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	12.8	125
17	Assessing reproducibility of matrix factorization methods in independent transcriptomes. Bioinformatics, 2019, 35, 4307-4313.	4.1	23
18	Recurrent activating mutations of PPARÎ ³ associated with luminal bladder tumors. Nature Communications, 2019, 10, 253.	12.8	44

#	Article	IF	CITATIONS
19	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
20	Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men. European Urology, 2019, 75, 11-15.	1.9	32
21	Abstract 1690: A tumor deconvolution DREAM Challenge: Inferring immune infiltration from bulk gene expression data. , 2019, , .		2
22	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480.	1.9	72
23	Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2018, 16, 266-273.	1.9	11
24	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	12.8	254
25	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Journal of the National Cancer Institute, 2018, 110, 68-77.	6.3	89
26	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988.	4.2	89
27	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncológica, 2018, 57, 498-508.	1.8	41
28	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612.	1.9	37
29	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology, 2018, 155, 1999-2013.e3.	1.3	347
30	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Frontiers in Oncology, 2018, 8, 390.	2.8	46
31	Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nature Communications, 2018, 9, 1978.	12.8	177
32	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. Oncologist, 2018, 23, 1500-1510.	3.7	6
33	Identification of Positively and Negatively Selected Driver GeneÂMutations Associated With Colorectal Cancer With Microsatellite Instability. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 277-300.	4.5	15
34	Abstract 4603: Clinical application and potential usefulness of targeted next-generation sequencing on resected pancreatic ductal adenocarcinoma. , 2018, , .		1
35	Abstract 4045: A novel transcriptomic-based immune classification of soft tissue sarcoma (STS) and its association with molecular characteristics, clinical outcome and response to therapy. , 2018, , .		2
36	Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i> , in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 3191-3202.	7.0	67

#	Article	IF	CITATIONS
37	Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates <i>ATM</i> in tumorigenesis: A proof of principle study. Genes Chromosomes and Cancer, 2017, 56, 788-799.	2.8	5
38	Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Reports, 2017, 21, 2458-2470.	6.4	148
39	Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. Journal of Clinical Investigation, 2017, 127, 1873-1888.	8.2	58
40	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort Journal of Clinical Oncology, 2017, 35, 3509-3509.	1.6	24
41	Metastatic clear cell renal cell carcinoma: Proangiogenic gene expression and outcome on sunitinib Journal of Clinical Oncology, 2017, 35, e16085-e16085.	1.6	0
42	Abstract 4396: Multiomics assessment of the cancer and stromal compartments of patient-derived pancreatic xenografts reveals clinically-relevant subtypes and novel targeted therapies. , 2017, , .		0
43	Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis. Frontiers in Cell and Developmental Biology, 2016, 4, 58.	3.7	63
44	Estimating theÂpopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology, 2016, 17, 218.	8.8	1,980
45	The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity. Molecular Biology of the Cell, 2016, 27, 2653-2661.	2.1	27
46	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nature Communications, 2016, 7, 11263.	12.8	73
47	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066.	7.0	433
48	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	2.2	160
49	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
50	Immuno-molecular characterization of colorectal cancer tumors and its clinical implications. Translational Cancer Research, 2016, 5, S368-S370.	1.0	1
51	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		0
52	Abstract A48: Multi-omics characterization of PDAC subtypes using PDX reveals that epigenetic but not genetic analysis permit a clinically relevant classification. , 2016, , .		0
53	Abstract B72: Pancreatic cancer cell drives stroma composition. , 2016, , .		0
54	Integrating tumor microenvironment with cancer molecular classifications. Genome Medicine, 2015, 7, 115.	8.2	2

#	Article	IF	CITATIONS
55	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	4.6	51
56	Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers. Molecular and Cellular Oncology, 2015, 2, e999507.	0.7	1
57	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339.	7.0	250
58	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
59	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	30.7	3,596
60	TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications, 2015, 6, 7207.	12.8	42
61	Receptor-Independent Ectopic Activity of <i>Prolactin</i> Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. Antioxidants and Redox Signaling, 2015, 23, 1-14.	5.4	12
62	Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation. , 2015, , .		0
63	IGF2 Promotes Growth of Adrenocortical Carcinoma Cells, but Its Overexpression Does Not Modify Phenotypic and Molecular Features of Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e103744.	2.5	40
64	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity. Clinical Cancer Research, 2014, 20, 5777-5786.	7.0	44
65	Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes. Cell Reports, 2014, 9, 1235-1245.	6.4	181
66	Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2014, 20, 1323-1334.	7.0	121
67	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	12.4	304
68	Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood, 2014, 124, 3772-3780.	1.4	36
69	Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology, 2014, 59, 2228-2237.	7.3	57
70	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
71	High-resolution analysis of DNA copy number alterations in rectal cancer. Strahlentherapie Und Onkologie, 2014, 190, 1028-1036.	2.0	4
72	Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature Medicine, 2014, 20, 167-174.	30.7	166

#	Article	IF	CITATIONS
73	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes Journal of Clinical Oncology, 2014, 32, 3511-3511.	1.6	34
74	Sporadic Early-Onset Colorectal Cancer Is a Specific Sub-Type of Cancer: A Morphological, Molecular and Genetics Study. PLoS ONE, 2014, 9, e103159.	2.5	119
75	Abstract 1075: Molecular determinants of colon and renal cancers' immune contextures. , 2014, , .		Ο
76	Extensive characterization of sphere models established from colorectal cancer cell lines. Cellular and Molecular Life Sciences, 2013, 70, 729-742.	5.4	21
77	Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E174-E184.	3.6	110
78	Identification of Gene Expression Profiles Associated With Cortisol Secretion in Adrenocortical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1109-E1121.	3.6	33
79	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
80	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	1.3	302
81	Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers. Science Translational Medicine, 2013, 5, 186ra66.	12.4	392
82	CD8â€alpha Tâ€cell infiltration in human papillomavirusâ€related oropharyngeal carcinoma correlates with improved patient prognosis. International Journal of Cancer, 2013, 132, E26-36.	5.1	82
83	CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica, 2013, 98, 1250-1258.	3.5	56
84	Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine, 2013, 10, e1001453.	8.4	1,064
85	A Poor Prognosis Subtype of HNSCC Is Consistently Observed across Methylome, Transcriptome, and miRNome Analysis. Clinical Cancer Research, 2013, 19, 4174-4184.	7.0	45
86	An essential role for decorin in bladder cancer invasiveness. EMBO Molecular Medicine, 2013, 5, 1835-1851.	6.9	45
87	ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. PLoS ONE, 2013, 8, e64536.	2.5	15
88	Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood, 2012, 119, 5795-5806.	1.4	99
89	An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Medical Genomics, 2012, 5, 54.	1.5	14
90	Clinical and Pathophysiological Implications of Chromosomal Alterations in Adrenocortical Tumors: An Integrated Genomic Approach. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E301-E311.	3.6	41

#	Article	IF	CITATIONS
91	Identity by Descent Mapping of Founder Mutations in Cancer Using High-Resolution Tumor SNP Data. PLoS ONE, 2012, 7, e35897.	2.5	8
92	Deletion of Chromosomes 13q and 14q Is a Common Feature of Tumors with BRCA2 Mutations. PLoS ONE, 2012, 7, e52079.	2.5	20
93	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics, 2011, 20, 3974-3985.	2.9	266
94	Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma. American Journal of Pathology, 2011, 178, 881-894.	3.8	48
95	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-Oncology, 2011, 13, 84-98.	1.2	115
96	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 2010, 115, 1226-1237.	1.4	285
97	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood, 2010, 116, 1092-1104.	1.4	122
98	Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. International Journal of Cancer, 2010, 126, 1882-1894.	5.1	194
99	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to antiâ€EGFR antibodies in colorectal cancer. International Journal of Cancer, 2010, 127, 1321-1331.	5.1	45
100	Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nature Medicine, 2010, 16, 781-787.	30.7	394
101	Reply to J.R. Anderson et al. Journal of Clinical Oncology, 2010, 28, e589-e590.	1.6	2
102	Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 2151-2158.	1.6	426
103	Transcriptome Analysis Reveals that p53 and β-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. Cancer Research, 2010, 70, 8276-8281.	0.9	134
104	Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20471-20476.	7.1	187
105	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Cancer, 2010, 9, 234.	19.2	37
106	Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Research, 2010, 12, R63.	5.0	54
107	Should We Abandon the t-Test in the Analysis of Gene Expression Microarray Data: A Comparison of Variance Modeling Strategies. PLoS ONE, 2010, 5, e12336.	2.5	120
108	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLoS ONE, 2009, 4, e7094.	2.5	203

#	Article	IF	CITATIONS
109	WNT/β atenin pathway activation in Wilms tumors: A unifying mechanism with multiple entries?. Genes Chromosomes and Cancer, 2009, 48, 816-827.	2.8	50
110	Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival. Journal of Clinical Oncology, 2009, 27, 1108-1115.	1.6	341
111	Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2—New Therapeutic Targets for Colorectal Cancers. Gastroenterology, 2009, 137, 1358-1366.e3.	1.3	47
112	Stabilization of \hat{I}^2 -catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology, 2008, 47, 247-258.	7.3	132
113	Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer. Cancer Cell, 2008, 14, 471-484.	16.8	443
114	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Molecular Cancer, 2008, 7, 41.	19.2	145
115	<i>KRAS</i> Mutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature. Journal of Clinical Oncology, 2008, 26, 2228-2230.	1.6	32
116	Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicinâ^'Cyclophosphamide Regimen. PLoS Medicine, 2007, 4, e90.	8.4	144
117	Tbx3 Is a Downstream Target of the Wnt/β-Catenin Pathway and a Critical Mediator of β-Catenin Survival Functions in Liver Cancer. Cancer Research, 2007, 67, 901-910.	0.9	147
118	Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood, 2007, 109, 3972-3981.	1.4	36
119	Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood, 2007, 109, 2156-2164.	1.4	182
120	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood, 2007, 109, 4952-4963.	1.4	533
121	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45, 42-52.	7.3	1,034
122	Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBLC) Blood, 2007, 110, 562-562.	1.4	0
123	Comparison of the latest commercial short and long oligonucleotide microarray technologies. BMC Genomics, 2006, 7, 51.	2.8	45